Key Takeaway: Agomab has reported its financial results for the first half of 2026, highlighting a significant regulatory alignment with the FDA regarding the NOV-ERA Phase 2b study design for Ontunisertib in Fibrostenosing Crohn’s Disease. The study features a novel primary endpoint focused on endoscopic passability. Additionally, topline data from an open-label long-term extension study was shared, indicating promising outcomes.
Market Sentiment Analysis
POSITIVE FACTORS
Regulatory alignment with the FDA on study design.
Introduction of a novel primary endpoint for the study.
Positive topline data from the long-term extension study.
Full Press Release Details
-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD), including Novel Primary Endpoint of Endoscopic Passability -- -- Topline Data from Open-Label Long-term Extension Study
Frequently Asked Questions
What did Agomab report for H1 2026?
Agomab reported its financial results for the first half of 2026.
What is the NOV-ERA Phase 2b study about?
It focuses on Ontunisertib for Fibrostenosing Crohn’s Disease.
What is the novel primary endpoint introduced?
The novel primary endpoint is endoscopic passability.
What data was shared from the extension study?
Topline data from an open-label long-term extension study was shared.